The use of xenograft models for the selection of cancer treatments with the EGFR as an example
- 3 December 2007
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 65 (3), 200-211
- https://doi.org/10.1016/j.critrevonc.2007.10.003
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor responseInternational Journal of Cancer, 2007
- Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126British Journal of Cancer, 2006
- Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude MiceClinical Cancer Research, 2006
- Gefitinib–trastuzumab combination on hormone-refractory prostate cancer xenograftEuropean Journal Of Cancer, 2005
- Preclinical models in cancer drug discovery and developmentEuropean Journal Of Cancer, 2004
- Clonogenic assay with established human tumour xenograftsEuropean Journal Of Cancer, 2004
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal Of Cancer, 2004
- “Of mice and men”European Journal Of Cancer, 2004
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal Of Cancer, 2004
- Modeling cancer in miceOncogene, 2002